SELLAS Life Sciences Group just beat Q1 estimates and is weeks from a pivotal trial readout — and more than 30% of its free float is still held short.
That tension is the whole story this week. SLS reported Q1 EPS of -$0.05 on Tuesday, beating the -$0.06 consensus, and headlines Wednesday morning described the company as "nearing a pivotal trial readout" in its leukemia pipeline. The stock has responded — up 7.2% on the week and 9.7% over the past month to $5.22. Yet short sellers have barely blinked. Short interest runs at roughly 30.6% of the free float, down only fractionally from around 31.3% a month ago. That divergence — a biotech rallying into a binary catalyst while bears hold firm — is exactly the kind of charged setup worth watching closely.
The borrow market underlines how entrenched the short base is. Availability has dropped to just 5.9% of short interest, meaning only about one share is still available to lend for every seventeen already borrowed. That is an extremely tight pool. Cost to borrow has eased from a monthly high near 16.3% in early April to 13.1% now, but it remains elevated — a cost that bears are willingly paying to keep the position on. The ORTEX short score of 86.6 places SLS in the 97th-or-so percentile for short pressure across the universe, and the days-to-cover reading from official FINRA data is 11.7 days, meaning covering the entire short book at current daily volumes would take nearly two and a half trading weeks. The lending pool has been near-fully used for months — utilization has not dropped below 85% since May 1, and it touched 100% as recently as April 2025.
Options positioning has edged toward more defensive territory this week, though without dramatic alarm bells. The put/call ratio moved to 0.074 — about 1.5 standard deviations above its 20-day mean of 0.066 — nudging toward the higher end of recent ranges. This week's PCR is not at a 52-week extreme (the high is 0.12, the low 0.006), but the uptick is notable given that calls have dominated SLS options flow for months. The options market, in other words, has not fully embraced the bull catalyst; a modest hedge has crept back in.
On the Street, analyst coverage of SLS is thin and mostly stale — the most recent action on record was Maxim Group raising its target from $7 to $10 in March 2026, maintaining a Buy. At $5.22 per share that implies meaningful upside to the sole active target, though thin coverage makes consensus figures less reliable for this name. The institutional picture is more telling: BlackRock recently added 4.6 million shares to hold 6.6% of the company, and Vanguard added 1.6 million shares. State Street's last reported position showed a 5.2 million-share addition. Passive index flows likely explain some of this — SLS was added to the S&P Biotechnology Select Industry Index in late March — but the aggregate direction from large holders has been accumulative.
Recent earnings have been modestly negative: the last three reported prints each produced a small negative next-day reaction of between -0.9% and -3.8%, with the longer-term five-day move also tipping negative in two of three instances. Tuesday's Q1 beat breaks that string, at least on first read. The next scheduled event is May 18 — a company event that may relate to the pivotal trial readout referenced in Wednesday's analyst commentary.
The question for the coming days is whether the Q1 beat and the trial milestone shift enough short-seller calculus to move that tightly-constrained borrow market. With availability near its lowest levels and days-to-cover above eleven, even a modest wave of covering has limited room to manoeuvre without meaningfully moving the stock.
See the live data behind this article on ORTEX.
Open SLS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
